FDA Under Pressure On Its Approach To Assigning Combo Product Jurisdiction
This article was originally published in The Gray Sheet
Executive Summary
A federal court handed down a potentially significant ruling related to FDA’s policies for designating primary product review responsibility to the drug, biologic or device center just days after members of Congress questioned FDA on its approach.
You may also be interested in...
Ball In Judge’s Court In Combination Product Classification Suit
All the planned briefs have been filed in a case, Prevor v. United States Food and Drug Administration, that could have important implications for how FDA designates a product for either device or drug primary review.
Ball In Judge’s Court In Combination Product Classification Suit
All the planned briefs have been filed in a case, Prevor v. United States Food and Drug Administration, that could have important implications for how FDA designates a product for either device or drug primary review.
Regulatory News In Brief
Breast implant advisory panel